Effects of Rifaximin Treatment and Retreatment in Nonconstipated IBS Subjects (Q37874146)

24 August 2017

title

Effects of rifaximin treatment and retreatment in nonconstipated IBS subjects (English)

1 reference

24 August 2017

Effects of Rifaximin Treatment and Retreatment in Nonconstipated IBS Subjects (English)

1 reference

https://api.crossref.org/works/10.1007/S10620-011-1728-5

1 December 2024

Mark Pimentel

1 reference

24 August 2017

Walter Morales

1 reference

24 August 2017

Kathleen Chua

1 reference

24 August 2017

Gillian Barlow

1 reference

24 August 2017

Stacy Weitsman

1 reference

24 August 2017

Gene Kim

1 reference

24 August 2017

Venkata Pokkunuri

1 reference

24 August 2017

Emily Rook

1 reference

24 August 2017

Ruchi Mathur

1 reference

24 August 2017

Zachary Marsh

1 reference

24 August 2017

Meridythe M. Amichai

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21559740

1 December 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21559740

1 December 2024

publication date

11 May 2011

1 reference

full work available at URL

24 August 2017

http://link.springer.com/content/pdf/10.1007/s10620-011-1728-5.pdf

1 reference

https://api.crossref.org/works/10.1007/S10620-011-1728-5

http://link.springer.com/article/10.1007/s10620-011-1728-5/fulltext.html

1 December 2024

1 reference

https://api.crossref.org/works/10.1007/S10620-011-1728-5

http://link.springer.com/content/pdf/10.1007/s10620-011-1728-5

1 December 2024

1 reference

https://api.crossref.org/works/10.1007/S10620-011-1728-5

Digestive Diseases and Sciences

1 December 2024

published in

1 reference

24 August 2017

1 reference

24 August 2017

1 reference

24 August 2017

page(s)

2067-2072

1 reference

Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: subanalysis of a double-blind randomized controlled study

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1728-5

A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1728-5

The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1728-5

Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1728-5

Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1728-5

Rifaximin: in vitro and in vivo antibacterial activity--a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1728-5

Effects of rifaximin on bacterial virulence mechanisms at supra- and sub-inhibitory concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1728-5

Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1728-5

Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1728-5

Abnormal breath testing in IBS: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1728-5

Small intestinal bacterial overgrowth in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1728-5

Prevalence of irritable bowel syndrome (IBS) and variability of diagnostic criteria.

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21559740

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Impact of irritable bowel syndrome: prevalence and effect on health-related quality of life.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21559740

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Irritable bowel syndrome and dyspepsia in the general population: Overlap and lack of stability over time

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21559740

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Reviews in gastroenterological disorders

HB El-Serag

2003

1 reference

https://api.crossref.org/works/10.1007/S10620-011-1728-5

1 December 2024

Identifiers

1 reference

24 August 2017

1 reference